Total trials
94
Active
17
Phase 3
6
Total enrollment
9,575
Pipeline matrix
Showing 9 of 9 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Resin infiltration | — | — | — | — | — | 1 | |
| Vanish XT varnish | — | — | — | — | — | 1 | |
| Dexamethasone Sodium Phosphate | — | — | — | — | — | 1 | |
| Silver diamine Fluoride 38% | — | — | — | — | — | 1 | |
| Silver diamine fluoride- potassium iodide | — | — | — | — | — | 1 | |
| Injectable Platelet Rich Fibrin | — | — | — | — | — | 1 | |
| 3D-printed Orthognathic Surgical Simulation | — | — | — | — | — | 1 | |
| 2D Visual Representations of Skeletal Movements in Orthognathic Surgery | — | — | — | — | — | 1 | |
| A- PRF | — | — | — | — | — | 1 |
Next readouts
- 2025-05-30
- 2025-06-30
- 2025-06-30
- 2025-08-30
- 2026-03
- 2026-05-31
Top conditions
- Dental Caries11
- COVID-193
- Pain3
- Behavior3
- SARS-CoV-22
- Gingivitis2
- Pulpotomy2
- Pain Perception of the New Device2
Frequently asked questions about King Abdulaziz University
- How many clinical trials does King Abdulaziz University have on ClinicalTrials.gov?
- King Abdulaziz University is listed as the lead sponsor on 94 clinical trials in ClinicalTrials.gov, 17 of which are currently active (recruiting, enrolling, or ongoing).
- How many of King Abdulaziz University's trials are in Phase 3?
- 6 of King Abdulaziz University's trials are in Phase 3, spread across 9 active drug programs.
- What therapeutic areas does King Abdulaziz University focus on?
- King Abdulaziz University's most-studied conditions on ClinicalTrials.gov are Dental Caries, COVID-19, Pain, Behavior, SARS-CoV-2.
- When are King Abdulaziz University's next clinical trial readouts?
- King Abdulaziz University has 6 upcoming primary-completion readouts tracked here; the soonest is “The Effect of Dexamethasone Submucosal Injection After Surgical Extraction of Lower Impacted Third Molars on Trismus and Edema”, expected around 2025-05-30.